Clinicians and patients often confuse drug names that sound alike. We conducted auditory perception experiments in the United States to assess the impact of similarity, familiarity, background noise and other factors on clinicians' (physicians, family pharmacists, nurses) and laypersons' ability to identify spoken drug names. We found that accuracy increased significantly as the signal-to-noise (S/N) ratio increased, as subjective familiarity with the name increased and as the national prescribing frequency of the name increased. For clinicians only, similarity to other drug names reduced identification accuracy, especially when the neighboring names were frequently prescribed. When one name was substituted for another, the substituted name was almost always a more frequently prescribed drug. Objectively measurable properties of drug names can be used to predict confusability. The magnitude of the noise and familiarity effects suggests that they may be important targets for intervention. We conclude that the ability of clinicians and lay people to identify spoken drug names is influenced by signal-to-noise ratio, subjective familiarity, prescribing frequency, and the similarity neighborhoods of drug names.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.socscimed.2010.01.042 | DOI Listing |
Nat Commun
December 2024
Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
The mechanism(s) underlying gut microbial metabolite (GMM) contribution towards alcohol-mediated cardiovascular disease (CVD) is unknown. Herein we observe elevation in circulating phenylacetylglutamine (PAGln), a known CVD-associated GMM, in individuals living with alcohol use disorder. In a male murine binge-on-chronic alcohol model, we confirm gut microbial reorganization, elevation in PAGln levels, and the presence of cardiovascular pathophysiology.
View Article and Find Full Text PDFHealth Res Policy Syst
December 2024
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Background: The access to anti-cancer medications is influenced by policies formed via the convergence of various stakeholders. The aim of this study is to identify and analyse the stakeholders involved in formulating and implementing policies related to the accessibility of anti-cancer medications in Iran and their interactions that are relevant to the outcomes of these policies for the first time.
Methods: To achieve the objectives, a novel multistage social network analysis (SNA)-based approach that includes three phases is proposed.
BMC Cancer
December 2024
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong, P.R. China.
Purpose: Antiangiogenesis therapy has become a hot field in cancer research. Given that tumor blood vessels often express specific markers related to angiogenesis, the study of these heterogeneous molecules in different tumor vessels holds promise for advancing anti-angiogenic therapy. Previously using phage display technology, we identified a targeting peptide named GX1 homing to gastric cancer vessels for the first time.
View Article and Find Full Text PDFFront Biosci (Elite Ed)
November 2024
Department of Life Sciences, GITAM School of Science, Gandhi Institute of Technology and Management, 530045 Visakhapatnam, Andhra Pradesh, India.
Background: Amalgamation of metal-tolerant plant growth promoting rhizobacteria (PGPR) with biochar is a promising direction for the development of chemical-free biofertilizers that can mitigate environmental risks, enhance crop productivity and their biological value. The main objective of the work includes the evaluation of the influence of prepared bacterial biofertilizer (BF) on biometric growth parameters as well as physiological and biochemical characteristics of rapeseed ( L.) at copper action.
View Article and Find Full Text PDFCureus
November 2024
Department of Plastic Surgery, University Hospital of Heraklion, Heraklion, GRC.
The Greco-Roman physician Galen of Pergamon was the first to mention a drug named Paccianon. This drug was unknown in ancient Greece and most probably through the School of Alexandria entered medical literature. Oribasius and Aetius were the only two practitioners who mentioned it after Galen, administrating it in various forms, such as poultice, mixture, and collyrium, for a series of ophthalmic diseases and cutaneous lesions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!